scholarly journals Anti-Mullerian Hormone (AMH) as a Predictor of Ovarian Response to Clomiphene Citrate in Polycystic Ovarian Syndrome

2021 ◽  
pp. 1-7
Author(s):  
Serajoom Munira ◽  
Jesmine Banu ◽  
Shakeela Ishrat ◽  
Mehnaz Mustary Shume ◽  
Muhammad Jasim Uddin ◽  
...  
Keyword(s):  
Ovulation Induction ◽  
Polycystic Ovary ◽  
Clomiphene Citrate ◽  
Follicle Stimulating Hormone ◽  
Negative Relationship ◽  
Poor Response ◽  
Ovarian Response ◽  
Cross Sectional ◽  
Follicle Size ◽  
Stimulating Hormone

Background: Serum Anti-Mullerian hormone (AMH) levels in women with polycystic ovary syndrome (PCOS) are two- to threefold higher than in ovulatory women with normal ovaries, corresponding to the two- to threefold increase in the number of small follicles in PCOS. The increased AMH has been hypothesized to reduce follicle sensitivity to follicle stimulating hormone (FSH) and estradiol production, thus preventing follicle selection, resulting in follicular arrest at the small antral phase with failure of dominance. Objective: The study was undertaken to test the hypothesis that high AMH level is associated with poor response to ovulation induction in PCOS women. Methods: This was a cross-sectional comparative study of 50 infertile women with PCOS, grouped into those with AMH level <8 ng/mL and those with AMH level [Formula: see text] 8 ng/mL. All participants received an initial dose of 100 mg/day of clomiphene citrate from 2nd to 6th day of menstrual cycle. Ovarian response (follicle size) was assessed by transvaginal monitoring on 12th day of cycle. Results: A total of 50 women were recruited, of which 4 dropped out. Women with AMH [Formula: see text] 8 ng/mL comprised only 23.91% of the PCOS women. AMH and day 12 follicle size had a statistically significant association. Adjusting for other confounding variables in linear, logarithmic, and logistic analysis, serum AMH had significant negative relationship with follicle size (r = 0.511, p < 0.001). AMH was also positively correlated with serum LH, testosterone and negatively correlated with serum follicle stimulating hormone (FSH), serum TSH and BMI. Conclusion: We observed that higher AMH level women had poor response to ovulation induction compared to women with low AMH level.

scholarly journals Clomiphene citrate resistance in relation to follicle-stimulating hormone receptor Ser680Ser-polymorphism in polycystic ovary syndrome

2009 ◽  
Vol 24 (8) ◽  
pp. 2007-2013 ◽  
Author(s):  
A. Overbeek ◽  
E.A.M. Kuijper ◽  
M.L. Hendriks ◽  
M.A. Blankenstein ◽  
I.J.G. Ketel ◽  
...  
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Hormone Receptor ◽  
Polycystic Ovary ◽  
Clomiphene Citrate ◽  
Follicle Stimulating Hormone ◽  
Ovary Syndrome ◽  
Stimulating Hormone

scholarly journals Success Rates of Clomiphene Citrate and Recombinant Gonadotropin Cycles: A Single-Center Experience

2019 ◽  
pp. 1
Author(s):  
Beril Gurlek ◽  
Ali Sertac Batioglu ◽  
Mine Kanat-Pektas ◽  
Ibrahim Kale ◽  
Ozgur Onal ◽  
...  
Keyword(s):  
Luteinizing Hormone ◽  
Ovulation Induction ◽  
Clomiphene Citrate ◽  
Follicle Stimulating Hormone ◽  
Clinical Pregnancy ◽  
Success Rates ◽  
Factors Associated ◽  
Single Center Experience ◽  
A Prospective Study ◽  
Stimulating Hormone

<p><strong>Objective:</strong> This aim of this study is to assess the ovulation induction cycles based on clomiphene citrate and gonadotropin administration and specify the factors associated with successful outcomes. </p><p><strong>Study Design:</strong> This is a prospective study of 631 patients who underwent 917 ovulation induction cycles. While clomiphene citrate was used in 680 cycles (74.2%) and recombinant follicle-stimulating hormone was administered in 237 cycles (25.8%). </p><p><strong>Results:</strong> A total of 153 pregnancies were achieved in 917 ovulation induction cycles, indicating a clinical pregnancy rate of 16.7%. The ovulation induction cycles which ended up with clinical pregnancy had a significantly lower frequency of smoking (p=0.005), shorter infertility duration (p=0.001), higher basal luteinizing hormone (p=0.021) and lower basal progesterone (p=0.008) than unsuccessful cycles. The clomiphene citrate cycles which ended up with clinical pregnancy had a significantly lower frequency of smoking (p=0.011), shorter infertility duration (p=0.001) and lower basal progesterone (p=0.013) than the unsuccessful cycles. The recombinant follicle-stimulating hormone cycles which ended up with clinical pregnancy had a significantly higher basal luteinizing hormone (p=0.008) than the unsuccessful cycles. Basal luteinizing hormone and progesterone concentrations could significantly distinguish the patients who were able to conceive in ovulation induction cycles (p=0.021 and p=0.008, respectively).</p><p><strong>Conclusions:</strong> Smoking, longer duration of infertility, and elevated basal progesterone are poor prognostic factors for clinical pregnancy in clomiphene citrate and recombinant follicle-stimulating hormone cycles.</p>

scholarly journals Pharmacogenomic Biomarkers of Follicle-Stimulating Hormone Receptor Malfunction in Females with Impaired Ovarian Response—A Genetic Survey

2021 ◽  
Vol 10 (2) ◽  
pp. 170
Author(s):  
Alireza Tafazoli ◽  
Sławomir Wołczyński ◽  
Natalia Wawrusiewicz-Kurylonek ◽  
Seyed-Alireza Esmaeili ◽  
Wojciech Miltyk
Keyword(s):  
Hormone Receptor ◽  
Follicle Stimulating Hormone ◽  
Poor Response ◽  
Ovarian Response ◽  
Perspective View ◽  
Fshr Gene ◽  
Genetic Survey ◽  
Critical Overview ◽  
Actionable Variants ◽  
Stimulating Hormone

Follicle-stimulating hormone receptor (FSHR) plays an essential role as one of the most important molecules in response to some of infertility related medications. Impaired ovarian reserve and poor response to such treatments are partially dependent on the FSHR molecule itself. However, the function and drug sensitivity for this receptor may change due to various allele and polymorphisms in the FSHR gene. Studies indicated some of the FSHR-mediated treatments utilized in clinical centers display different outcomes in specific populations, which may arise from FSHR altered genotypes in certain patients. To support the increased demands for reaching the personalized drug and hormone therapy in clinics, focusing on actionable variants through Pharmacogenomic analysis of this receptor may be necessary. The current study tries to display a perspective view on genetic assessments for Pharmacogenomic profiling of the FSHR gene via providing a systematic and critical overview on the genetics of FSHR and its diverse responses to ligands for infertility treatment in females with impaired ovarian responses and show the potential effects of the patient genetic make-up on related binding substances efficacy. All identified functional drug-related alleles were selected through a comprehensive literature search and analyzed. Advanced technologies for the genetic evaluation of them are also discussed properly.

Sign in / Sign up

Export Citation Format

Share Document